Navigation Links
London Genetics Expands its Senior Advisory Team
Date:7/22/2010

LONDON, July 22, 2010 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, is pleased to announce that it has augmented the strength of its team with the appointment of two senior advisers, Professors Stephen DeCherney and Munir Pirmohamed. With their extensive clinical, healthcare, and drug development expertise, their guidance will be invaluable to London Genetics.

Stephen DeCherney MD, MPH, is Professor of Medicine at the University of Carolina, and was previously President, Global Clinical Organisation and Chief Innovation Officer at Quintiles Transnational Corporation. With research interests in internal medicine, endocrinology and diabetes, Professor DeCherney spent five years at the US National Institutes of Health, followed by various management roles at the Christiana Care Health System in Delaware, where he was principal investigator in more than 100 clinical trials. He is on the Board of Certara, Inc and has an MPH from Columbia University School of Public Health.

As holder of the NHS Chair of Pharmacogenetics at the University of Liverpool, Professor Munir Pirmohamed MB, ChB (Hons), PhD, FRCP, FRCP(E) is a leading researcher in the area of pharmacogenetics and drug safety. He is involved in the European EU-PACT Phase IV study, which is looking at the effect of gene-based dosing of warfarin on 2000 patients, and is expected to provide an important indication of the value pharmacogenetics can bring to clinical practice. After qualifying in medicine, Professor Pirmohamed obtained a PhD in pharmacology, and is Deputy Director of the MRC Cent
'/>"/>

SOURCE London Genetics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London
2. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
3. The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program
4. Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010
5. New Appointments at London Genetics to Drive Strategy Forward
6. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
7. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
8. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
9. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
10. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
11. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Boston’s Adult Stem Cell Technology Center, LLC ... stem cell biotechnologies. Currently the company holds seven ... patent applications currently under examination by the U.S. Patent ... of the most vexing problems in adult stem cell ... are difficult to identify; and they have been difficult ...
(Date:7/30/2014)... , July 30, 2014 Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... results and highlights for the quarter ended June 30, ... financial markets close. Regulus will host ... 2014, at 5:00 pm Eastern Daylight Time to discuss ...
(Date:7/30/2014)... W. R. Grace & Co. (NYSE: ... REVELERIS® Prep purification system , a dual-mode instrument ... researchers to perform both flash and preparative liquid ... the REVELERIS® Prep purification system, researchers can easily ... a simple touch of the screen, giving them ...
(Date:7/30/2014)... July 30, 2014 A study presented ... safety and efficacy of CSL Behring,s C1 Inhibitor ... transplants in highly sensitized patients. C1-INH is a ... complement system. The study shows that ... in the levels of complement components 3 and ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Grace Launches New REVELERIS® Prep Purification System 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... 0 clinical testing has been gaining acceptance and ... development process in the years to come. The ... and technology dependence is also expected to result ... in this sector.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )"There is every ...
... Health Care Business Conference, an MBA-student organized event, will be held ... distinguished speakers and panelists from Healthcare Services, Investment, Pharma, Biotech, and ... ... 10, 2009 -- The 2009 Wharton Health Care Business Conference ...
... Feb. 10 DSM Biologics and Crucell N.V. (Euronext, ... today that they have entered into an agreement with ... Vendor Network. Under the terms of the agreement, Bioceros ... licensees of the PER.C6(R) cell line located in the ...
Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 314th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 3DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 4DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 5
(Date:7/31/2014)... LA Dr. Oren Tessler, Assistant Professor of Clinical ... of Medicine, is part of a team of plastic ... using a method to screen and select patients for ... of the patients who underwent this surgery to decompress ... got a bonus cosmetic eyelid surgery. The study, which ...
(Date:7/31/2014)... NXT-ID, Inc., (NXTD: OTCQB) a biometric authentication company ... and consumers wanting to learn more about its  ... on-air today, July 31 st . ... featured in a segment of NewsWatch, a weekly ... the History Channel, FYI Network today. ...
(Date:7/30/2014)... by the Red Queen in Lewis Carroll,s Through ... Illinois and National University of Singapore improved a ... evolve over decades to millions of years. , ... for competition, incorporates the "Red Queen Effect," an ... the 1970s, which suggests that organisms must constantly ...
Breaking Biology News(10 mins):Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 3Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... choices for our nation,s schoolchildren is a hot-button issue ... team of researchers from Cornell University have recently identified ... vegetables and salad items. Laura Smith, a researcher ... findings of the study "Convenience Drives Choice in School ...
... Inc. (Nasdaq: OKSB ), ("Southwest"), today announced that it has priced its ... the public of $12.50 per share for net proceeds of approximately ... size of approximately $40 million .  The offering is expected to close ... , , ...
... PHILADELPHIA , April 27 Mondre Energy, Inc. (MEI), a ... Exeter Associates to address a wide range of energy issues on behalf ... Power Plant Research Program works to ensure that Maryland meets ... , , ...
Cached Biology News:Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 2Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 3Mondre Energy Partnering with Exeter Associates to Address Energy Issues in Maryland 2
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
... pACHLT-A-BFP Baculovirus Transfer Vector is a derivative of ... gene for blue fluorescent protein (BFP), followed by ... (MCS).,Foreign genes are expressed as BFP-6xHis fusion proteins ... enzyme,sites (EcoR I, Stu I, Sac I, Not ...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Biology Products: